Application of theaflavin as synergist of antifungal medicine
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
An antifungal drug, theaflavin technology, applied in the field of medicine, can solve the problems of no fungal disease, no antifungal effect, etc., and achieve the effects of improving the antifungal effect, saving medical expenses, and reducing the dosage of drugs
Inactive Publication Date: 2010-09-01
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF3 Cites 4 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Theaflavins also have antibacterial effects, but have no antifungal effects, and there are no re
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0006] Example 1: Effects of theaflavin and fluconazole in combination on different clinical fungal strains
[0007] Materials and methods
[0008] 1. Test drug:
[0009] Theaflavins: Wuhan Yuancheng Technology Development Co., Ltd.
[0010] Fluconazole injection: Pfizer Pharmaceutical Co., Ltd., batch number 9167802.
[0012] Theaflavin is made into solution with dimethyl sulfoxide, the concentration is 6.4mg / ml. All reagents were stored at -20°C. Before the experiment, the drug was taken out and placed in a 35°C incubator to melt, mixed well, and pharmacodynamic tests were carried out respectively.
[0013] 2. Strains:
[0014] Clinical strains: drug-resistant Candida albicans, including five strains 103, 17, 18, 38, and 0710448, and Candida tropicalis, including five strains 409, 936, 422, 0710453, and 0710087, all provided by the Mycology Department of Shanghai Changhai Hospital. Clinical samples fr...
Embodiment 2
[0043] Example 2: Combination of theaflavins and other azole antifungal drugs
[0044] Materials and methods
[0045] 1. Drugs
[0046] Itraconazole: Provided by the School of Pharmacy, Second Military Medical University
[0047] Ketoconazole: Provided by the School of Pharmacy, Second Military Medical University
[0048] Miconazole: Provided by the School of Pharmacy, Second Military Medical University
[0049] Itraconazole, ketoconazole and miconazole dimethyl sulfoxide were formulated to 6.4 mg / ml, theaflavins were formulated to 6.4 mg / ml with dimethyl sulfoxide, and each reagent was stored at -20°C. Before the experiment, the drug was taken out and placed in a 35°C incubator to melt, mixed well, and pharmacodynamic tests were carried out respectively.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention relates to the technical field of medicines, in particular to new application of theaflavin as a synergist of antifungal drugs. Through in vitro experiments, when used together with fluconazole, itraconazole, miconazole, ketoconazole and other antifungal drugs, theaflavin can increase therapeutic effect on slight surface and deep fungus infection to some extent and can restore the effect of the antifungal drugs on drug-resisting fungi. Therefore, the theaflavin can be used as the synergist of the antifungal drugs. The invention provides new application for the theaflavin; when used as the synergist of the antifungal drugs, the theaflavin not only can increase the antifungal effect of the drugs, but also can restore the effect of the antifungal drugs on the drug-resisting fungi in the condition that clinic fungal drug resistance is more and more common and drug resistance degree is more and more serious. The application dosage of the antifungal drugs can be reduced, so that medical expenses can be saved for patients, and the toxic and side effects of the drugs are reduced.
Description
technical field [0001] The invention relates to the technical field of medicine, and relates to a new application of theaflavin as a synergist for antifungal drugs. Background technique [0002] Theaflavin is one of the tea polyphenols. Studies have shown that theaflavin has the effect of regulating blood lipids, preventing cardiovascular diseases, and has a unique function of lowering blood lipids. Theaflavins are not only an effective free radical scavenger and anti Oxidant, and has various physiological functions such as anti-cancer, anti-mutation, improvement and treatment of cardiovascular and cerebrovascular diseases, and treatment of diabetes. Its role in food, medicine and health care is becoming more and more prominent. Theaflavins also have antibacterial effects, but have no antifungal effects, and there are no reports of their combined use as a synergist and antifungal drugs to treat fungal diseases. Contents of the invention [0003] The invention provides a n...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more